SG Americas Securities LLC bought a new stake in Regenxbio Inc (NASDAQ:RGNX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 18,777 shares of the biotechnology company’s stock, valued at approximately $619,000. SG Americas Securities LLC owned approximately 0.06% of Regenxbio as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of RGNX. Vanguard Group Inc. grew its holdings in shares of Regenxbio by 23.2% in the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after purchasing an additional 184,700 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Regenxbio by 3.6% in the first quarter. Geode Capital Management LLC now owns 171,346 shares of the biotechnology company’s stock valued at $3,306,000 after purchasing an additional 5,949 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Regenxbio by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock valued at $1,423,000 after purchasing an additional 4,275 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Regenxbio by 1.2% in the first quarter. Bank of America Corp DE now owns 51,380 shares of the biotechnology company’s stock valued at $992,000 after purchasing an additional 597 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Regenxbio by 31.4% in the first quarter. Goldman Sachs Group Inc. now owns 35,300 shares of the biotechnology company’s stock valued at $681,000 after purchasing an additional 8,429 shares in the last quarter. 68.73% of the stock is owned by hedge funds and other institutional investors.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction on Friday, September 15th. The shares were sold at an average price of $27.39, for a total transaction of $136,950.00. Following the completion of the transaction, the chief financial officer now directly owns 99,594 shares of the company’s stock, valued at $2,727,879.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Curran Simpson sold 2,000 shares of Regenxbio stock in a transaction on Monday, November 27th. The stock was sold at an average price of $29.31, for a total transaction of $58,620.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $1,216,365. The disclosure for this sale can be found here. Insiders have sold 122,110 shares of company stock valued at $3,757,720 over the last ninety days. 17.00% of the stock is owned by insiders.

A number of research analysts recently weighed in on RGNX shares. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Saturday, August 12th. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Evercore ISI started coverage on shares of Regenxbio in a report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Chardan Capital reissued a “buy” rating and issued a $75.00 target price (up from $55.00) on shares of Regenxbio in a report on Tuesday, September 5th. Finally, Bank of America raised their target price on shares of Regenxbio from $29.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $42.43.

Regenxbio Inc (RGNX) opened at $31.75 on Friday. Regenxbio Inc has a one year low of $16.30 and a one year high of $36.10.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.04. The company had revenue of $1.34 million during the quarter. Regenxbio had a negative net margin of 1,549.85% and a negative return on equity of 40.88%. sell-side analysts predict that Regenxbio Inc will post -2.71 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “18,777 Shares in Regenxbio Inc (RGNX) Purchased by SG Americas Securities LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/18777-shares-in-regenxbio-inc-rgnx-purchased-by-sg-americas-securities-llc/1753270.html.

Regenxbio Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.